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LETTERS
Liver stiffness measurement by
transient elastography predicts
early recovery from acute
hepatitis
We read with interest the lead article by
Casterà and Pinzani,1 particularly the
comment regarding the role of transient
elastography (TE) in the context of acute
hepatitis (AH).
The assumption that liver stiffness is
determined exclusively by hepatic ﬁbrosis
has been challenged by evidence that
patients with AH can have high values of
liver stiffness measurement (LSM) by TE.2
AH is a suitable model for studying the
kinetics of LSM, since inﬂammation and
necrosis increase rapidly and sometimes
massively, but may revert with equal speed.
We evaluated 92 consecutive patients
(mean age 41.8616.3 years, 71.7% males)
with symptomatic AH to assess how LSM
was inﬂuenced by aetiology, and whether
LSM kinetics correlated with the clinical
course of AH. Twelve patients (13%)
had acute hepatitis A virus (AHAV), 34
(37%) acute hepatitis B virus (AHBV), 26
(28.3%) acute hepatitis C virus (AHCV) and
20 (21.7%) drug-induced liver injury (DILI).
TE was performed at the onset of symptoms
of AH, and at 4, 8 and 12 weeks. At the onset
of AH, all patients had values of serum
alanine aminotransferase (ALT) at least 10
times above the upper normal limit, and
jaundice was present in 70, 60, 42 and 27%
of patients with AHBV, DILI, AHAV and
AHCV, respectively (p¼0.009). The median
value of LSM was 12.2 kPa (range 3.6e45.0),
and LSM correlated with ALT (r¼0.346,
p¼0.001) and bilirubin (r¼0.349, p¼0.001).
LSM was signiﬁcantly different in the four
groups of patients (p¼0.003), and LSM
>12 kPa, the predictive cut-off for the diag-
nosis of cirrhosis, was observed in 64, 46, 40
and 8% of patients with AHBV, AHCV, DILI
and AHAV, respectively (p¼0.010). Four
patients with severe acute AHBV received
lamivudine, one with severe DILI received
steroids, and 20 with AHCV received inter-
feron treatment. A progressive and signiﬁ-
cant reduction in LSM was observed in all
groups of patients during follow-up. In the
fourth week, 27, 38, 40 and 100% of patients
with AHBV, AHCV, DILI and AHAV,
respectively, had LSM <7 kPa. At week 8, the
percentage of patients with LSM <7 kPa was
37, 50 and 50% for AHBV, AHCV and DILI,
respectively. At week 12, the percentage of
patients with LSM <7 kPa was 44, 58 and
66% for AHBV, AHCVand DILI, respectively
(ﬁgure 1). To identify whether biochemical
parameters and LSM predict the clinical
course of AH, patients were analysed for
early clinical recovery from AH (normal
serum ALT values at week 4). By logistic
regression analysis LSM was the only
variable at presentation associated with
early clinical recovery (OR 0.727, 95% CI
0.599 to 0.882, p¼0.001). The receiver oper-
ating characteristic (ROC) analysis for
the model was 0.84, and the best cut-off of
LSM for identifying patients with early
clinical recovery was 9.5 kPa (sensitivity
83%, speciﬁcity 70%, positive predictive
value 41%, negative predictive value 96%,
positive likelihood ratio (LR) 2.86 and nega-
tive LR 0.16).
We concluded that LSM has a wide range
of values in AH, reﬂecting different mecha-
nisms of liver injury. In patients with AHAV
who have prevalently a necrotic injury with
scarce portal and periportal lymphocytic
inﬁltration,3 LSM rarely increases up to the
values observed in patients with cirrhosis.
Conversely, severe immune-mediated
lymphocytic inﬁltration4 5 can be the
substrate for the increase in LSM in patients
with AHBV or AHCV, and both inﬂamma-
tory mechanisms and cholestasis6 can
increase LSM in patients with DILI. Finally,
LSM is independently associated with early
clinical recovery and could be used to
monitor patients with AH.
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Immediate effect on fertility of
a gluten-free diet in women with
untreated coeliac disease
In a recent paper inGut, describing a Swedish
population-based cohort, Zugna et al found
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Figure 1 Kinetics of liver stiffness measurement (LSM) during the clinical course of the different
groups. AHAV, acute hepatitis A virus; AHBV, acute hepatitis B virus; AHCV, acute hepatitis C
virus; DILI, drug-induced liver injury.
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